Advertisement

Search Results

Advertisement



Your search for Kathleen Moore, MD, MS,Kathleen Moore, MD, MS matches 16 pages

Showing 1 - 16


gynecologic cancers

ARTISTRY-7 and ROSELLA: Phase III Trials to Evaluate Novel Agents in Platinum-Resistant Ovarian Cancer

Platinum resistance occurs in almost all patients whose ovarian cancer recurs. Single-agent chemotherapies are commonly used in this setting, but outcomes are generally poor, leaving a large unmet need for effective treatment. At the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on...

Expert Point of View: Kathleen Moore, MD, MS

“I think the NOW trial is a great study,” said Kathleen Moore, MD, MS, the Virginia Kerley Cade Endowed Chair in Cancer Developmental Therapeutics and Professor of Gynecologic Oncology at the University of Oklahoma Health Sciences Center, Oklahoma City, who shared her thoughts on the trial with The ...

gynecologic cancers

De-escalation of Surgery Feasible for Selected Patients With Low-Risk, Early-Stage Cervical Cancer

Many patients with early-stage, low-risk cervical cancer may be spared the side effects associated with radical hysterectomy and undergo simple hysterectomy with pelvic lymph node dissection instead, according to results of the international phase III SHAPE study presented at the 2023 ASCO Annual...

gynecologic cancers

MIRASOL Trial: First Targeted Therapy for Platinum-Resistant Ovarian Cancer to Improve Survival Outcomes

Mirvetuximab soravtansine-gynx, a novel antibody-drug conjugate, significantly improved progression-free and overall survival in patients with platinum-resistant, recurrent ovarian cancers that express high levels of folate receptor–alpha (FR-alpha), according to the results of the phase III...

gynecologic cancers
immunotherapy

Mirvetuximab Soravtansine Improves Survival in Patients With Recurrent Ovarian Cancer

The international phase III MIRASOL randomized clinical trial found that mirvetuximab soravtansine-gynx, an antibody and microtubule inhibitor conjugate, significantly improved progression-free and overall survival for patients with platinum-resistant, advanced high-grade epithelial ovarian,...

gynecologic cancers

Simple Hysterectomy May Be a Safe Option for Patients With Early-Stage, Low-Risk Cervical Cancer

Simple hysterectomy with pelvic lymph node dissection may be a safe treatment option for patients with early-stage, low-risk cervical cancer and may help improve quality of life, according to results from the large, international phase III SHAPE clinical trial. The research was presented by Plante...

Expert Point of View: Kathleen Moore, MD, MS

Kathleen Moore, MD, MS, the Virginia Kerley Cade Endowed Chair in Cancer Developmental Therapeutics and Professor of Gynecologic Oncology at the University of Oklahoma Health Sciences Center, spoke with The ASCO Post about GOG-258. According to Dr. Moore, the final results of this long-running...

gynecologic cancers

ARTISTRY-7 and ROSELLA: Phase III Trials to Evaluate Novel Agents in Platinum-Resistant Ovarian Cancer

Platinum resistance occurs in almost all patients whose ovarian cancer recurs. Single-agent chemotherapies are commonly used in this setting, but outcomes are generally poor, leaving a large unmet need for effective treatment. At the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on...

Expert Point of View: Kathleen Moore, MD, MS

“I think the NOW trial is a great study,” said Kathleen Moore, MD, MS, the Virginia Kerley Cade Endowed Chair in Cancer Developmental Therapeutics and Professor of Gynecologic Oncology at the University of Oklahoma Health Sciences Center, Oklahoma City, who shared her thoughts on the trial with...

Expert Point of View: Kathleen Moore, MD, MS

Kathleen Moore, MD, MS, the Virginia Kerley Cade Endowed Chair in Cancer Developmental Therapeutics and Professor of Gynecologic Oncology at the University of Oklahoma Health Sciences Center, spoke with The ASCO Post about GOG-258. According to Dr. Moore, the final results of this long-running...

Robin Zon Elected ASCO President for 2024–2025 Term; Other Leadership Positions Filled

ASCO has elected Robin Zon, MD, FACP, FASCO, a long-time member and volunteer, as its President beginning in June 2024. Dr. Zon will take office as President-Elect immediately following the ASCO Annual Business Meeting in Chicago on June 5, 2023. Five additional members were elected to the ASCO...

Robin Zon, MD, FACP, FASCO, Elected ASCO President for 2024–2025 Term

ASCO has elected Robin Zon, MD, FACP, FASCO, a long-time member and volunteer, to lead as its President beginning in June 2024. Dr. Zon will take office as President-Elect immediately following the ASCO Annual Business Meeting in Chicago on June 5, 2023. Five additional members were also elected to ...

ASCO Announces Election Candidates, Voting Opens on November 2

The ASCO Nominating Committee has selected 11 distinguished members as candidates for open leadership positions within the Society. Voting members are urged to vote in the election beginning November 2, 2022. Voting will close on December 6, 2022. President-Elect (4-year term) Robin Zon, MD, FACP, ...

gynecologic cancers

ARIEL4 Confirms Rucaparib’s Efficacy in Recurrent, BRCA-Mutated Ovarian Cancer: Does It Tell Us Anything New?

In March 2022, Kristeleit et al reported the results of the ARIEL4 trial1 of rucaparib in relapsed BRCA-mutant ovarian cancer in The Lancet Oncology (summarized in this issue of The ASCO Post) and are to be congratulated on this accomplishment. This report, along with the almost simultaneous...

Conquer Cancer 2018 Awards Presented at ASCO Annual Meeting

The Conquer Cancer Foundation of the ASCO recently announced the recipients of its 2018 ASCO Annual Meeting Merit Awards, Medical Student Rotations for Underrepresented Populations (MSR), Resident Travel Awards for Underrepresented Populations (RTA), and Long-term International Fellowship (LIFe)....

Conquer Cancer Foundation Recognizes 70 Young Oncology Researchers’ Findings With Merit Awards

ASCO’s Conquer Cancer Foundation is pleased to announce the recipients of its Merit Awards in gastrointestinal cancers, clinical immuno-oncology, genitourinary cancers, and cancer survivorship. The following 70 researchers— oncology fellows and trainees honored for the quality and scientific merit...

Advertisement

Advertisement




Advertisement